[{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Stem Cell engraftment","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Stem Cell engraftment","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Stem Cell engraftment","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"National Institute of Diabetes and Digestive Kidney Disease","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Dexamethasone","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"AVM Biotechnology \/ National Institute of Diabetes and Digestive Kidney Disease","highestDevelopmentStatusID":"4","companyTruncated":"AVM Biotechnology \/ National Institute of Diabetes and Digestive Kidney Disease"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AVM Biotechnology \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ National Cancer Institute"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AVM Biotechnology \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by AVM Biotechnology

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AVM0703 is small molecule immunomodulatory drug enrolling Phase 2 trials in US in relapsed/refractory Non-Hodgkin's Lymphoma (NHL) which began enrollment Q3 2023 (partially funded by NCI Ph II FastTrak grant 1R44CA272096).

                          Brand Name : AVM0703

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 01, 2023

                          Lead Product(s) : Dexamethasone Sodium Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AVM0703 (Dexamethasone sodium phosphate) is a small molecule which triggers the production and release of endogenous bispecific gamma delta TCR+ invariant TCR+ Natural Killer T-like cells (AVM-NKT).

                          Brand Name : AVM0703

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 14, 2022

                          Lead Product(s) : Dexamethasone Sodium Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : National Cancer Institute

                          Deal Size : $2.0 million

                          Deal Type : Funding

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AVM0703 (dexamethasone) led to, complete response in 27% of immune-resistant mouse A20 tumors as monotherapy and complete response in 60% when combined with 2 doses of cyclophosphamide/fludarabine (CyFlu).

                          Brand Name : AVM0703

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 01, 2022

                          Lead Product(s) : Dexamethasone Sodium Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AVM0703 is a small molecule which triggers the production and release of endogenous bispecific gamma delta TCR+ and invariant TCR+ Natural Killer T-like cells (AVM-NKT).

                          Brand Name : AVM0703

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 19, 2022

                          Lead Product(s) : Dexamethasone

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : T1D is an autoimmune disease that destroys beta cells, the insulin-making cells in the pancreas. This award provides an endorsement of AVM0703’s potential in two distinct and crucial therapeutic areas, diabetes and cancer.

                          Brand Name : AVM0703

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 05, 2022

                          Lead Product(s) : Dexamethasone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : National Institute of Diabetes and Digestive Kidney Disease

                          Deal Size : $1.6 million

                          Deal Type : Funding

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : This second study will evaluate AVM0703 in two different ARDS patient populations: one with COVID-19-mediated moderate to severe ARDS and the other with Influenza-mediated severe ARDS.

                          Brand Name : AVM0703

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 16, 2020

                          Lead Product(s) : Dexamethasone Sodium Phosphate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AVM Biotechnology has been awarded a National Cancer Institute Small Business Innovation Research Grant from the NIH to study the use of AVM0703 as a preconditioning agent to allow safe and efficient delivery of therapeutic immune cells for cancer treatm...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 11, 2020

                          Lead Product(s) : Dexamethasone Sodium Phosphate,Hydrocortisone,Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AVM Biotechnology received clinical trial approval for AVM0703. Unlike chemotherapy and radiation, AVM0703 spares platelets and red blood cells, limiting the need for transfusions.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 14, 2020

                          Lead Product(s) : Dexamethasone Sodium Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank